MT1P1: A Pseudogene with Potential as A Drug Target (G493987)

Target Name: MT1P1

NCBI ID: G493987

MT1P1

Other Name(s): metallothionein 1 pseudogene 1 | Metallothionein 1 pseudogene 1 | bA435O5.3

MT1P1: A Pseudogene with Potential as A Drug Target

MT1P1, also known as metallothionein 1 pseudogene 1, is a gene that encodes a protein known as metallothionein 1 (MT1). MT1 is a thyroid hormone that plays a critical role in regulating metabolism and helping the body to cope with environmental stressors. It is produced by the thyroid gland, and its levels are regulated by a number of different factors, including genetics, hormones, and environmental stressors.

MT1P1 is a pseudogene, which means that it is a genetic copy of a gene that does not actually code for a functional protein. Instead, it serves as a template for the production of the MT1 protein. TheMT1 gene is located on chromosome 18, and it is one of several genes that have been identified as potential drug targets for a variety of diseases.

One of the key features of MT1P1 is its ability to interact with a variety of different molecules, including thyroid hormones, cytokines, and growth factors. This makes it an attractive target for researchers who are looking for new ways to treat a variety of different conditions.

One of the potential benefits of MT1P1 as a drug target is its ability to modulate the activity of other genes. For example, studies have shown that MT1P1 can interact with the gene for the tumor necrosis factor-alpha (TNF-alpha), which is a protein that plays a role in the regulation of cell growth and differentiation. By modulating the activity of TNF-alpha, MT1P1 may be able to contribute to the development and progression of a variety of different diseases.

Another potential benefit of MT1P1 as a drug target is its ability to modulate the activity of the immune system.MT1P1 has been shown to interact with the immune system molecule known as PD-1, which is a protein that plays a role in regulating the immune response. This interaction may allow MT1P1 to contribute to the development of cancer, as the immune system may be able to recognize and attack cells that contain the MT1P1 protein.

In addition to its potential ability to modulate the activity of other genes and immune system molecules, MT1P1 is also of interest as a potential drug target because of its association with a variety of different diseases. For example, studies have shown that MT1P1 is often expressed at higher levels in tissues from patients with a variety of different conditions, including cancer, autoimmune diseases, and obesity. This suggests that MT1P1 may be a useful biomarker for the diagnosis and treatment of these conditions.

Overall, MT1P1 is a gene that has the potential to be a drug target for a variety of different diseases. Its ability to interact with a variety of different molecules, including thyroid hormones and immune system molecules, makes it an attractive target for researchers who are looking for new ways to treat a variety of different conditions. While more research is needed to fully understand the potential benefits and risks of MT1P1 as a drug target, its association with a variety of different diseases makes it a promising molecule for further study.

Protein Name: Metallothionein 1 Pseudogene 1

The "MT1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MT1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets